The nuclear transportation of PD-L1 and the function in tumor immunity and progression
Liyan Qu1, Jiakang Jin2,3, Jianan Lou2,3
1Clinical Laboratory Centre, 2nd Affiliated Hospital, School of Medicine, Zhejiang University, #88 Jie Fang Road, Hangzhou, 310009, Zhejiang, People's Republic of China.
Abstract:
As the main immune checkpoint, PD-L1-PD-1 interaction plays a critical role in the dysregulation of effector T cells, which contributes to the failure of Chimeric Antigen Receptor T-cell (CAR-T) and other immunotherapies. Presently, most research focuses on the extracellular function of PD-L1. Membrane PD-L1 can interact with its receptor PD-1 and decrease T cell-induced cancer immunity. However, the function of PD-L1 in cancer cells is still unclear. Recent studies have shown the separated clinical significance of PD-L1 expression in various cancer types, showing the complexity of PD-L1 in cancer cell regulation. As a novel regulatory pathway, the nuclear translocation of PD-L1 in cancer cells receives more attention. Results of these preclinical studies demonstrated that nuclear PD-L1 has an essential role in cancer development and other immune checkpoint molecules transcription. Herein, we summarized the mechanisms involved in PD-L1 nuclear transportation and identify the key regulatory factors in this process. Furthermore, we also summarize the function of nuclear PD-L1 in cancer immunity. These findings suggested the novel PD-L1 regulation in cancer development, which showed that nuclear PD-L1 is a potential therapeutic target in future cancer therapy.
Insights
Nuclear PD-L1, a novel regulator in cancer cells, impacts cancer immunity and development. Targeting nuclear PD-L1 offers a promising therapeutic strategy for future cancer treatments.
Area of Science:
- Oncology
- Immunology
- Cell Biology
Background:
- The PD-L1/PD-1 interaction is a key immune checkpoint affecting T cell function and immunotherapy success.
- Current research primarily addresses the extracellular roles of PD-L1, leaving its intracellular functions in cancer cells largely unexplored.
- Emerging evidence highlights the clinical significance and regulatory complexity of PD-L1 expression within cancer cells.
Purpose of the Study:
- To review the mechanisms governing PD-L1 nuclear translocation in cancer cells.
- To identify key regulatory factors involved in nuclear PD-L1 transport.
- To summarize the role of nuclear PD-L1 in cancer immunity and development.
Main Methods:
- Literature review of preclinical studies on PD-L1 nuclear translocation.
- Analysis of identified regulatory pathways and factors.
- Synthesis of data on nuclear PD-L1 functions in cancer immunity.
Main Results:
- Nuclear translocation of PD-L1 represents a novel regulatory pathway in cancer cells.
- Nuclear PD-L1 plays a crucial role in cancer development.
- Nuclear PD-L1 influences the transcription of other immune checkpoint molecules.
Conclusions:
- Nuclear PD-L1 is implicated in cancer development and immune regulation.
- Understanding nuclear PD-L1 mechanisms provides insights into novel cancer regulation.
- Nuclear PD-L1 emerges as a potential therapeutic target for future cancer therapies.
Related Concept Videos
02:23Abnormal Proliferation
01:45Regulation of Nuclear Protein Sorting
01:27Tumor Immunotherapy
01:46Nuclear Localization Signals and Import
01:42Directionality of Nuclear Transport
02:07Tumor Progression
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...